Kim S, Kim HJ A step forward towards personalised immunosuppressive therapy in neuromyelitis optica spectrum disorder J Neurol Neurosurg Psychiatry Published Online First: 12 June 2017. doi: 10.1136/jnnp-2017-315768
Su-Hyun Kim, Ho Jin Kim
In neuromyelitis optica spectrum disorder (NMOSD), early initiation of effective immunosuppressive therapy to prevent further relapse is imperative because even a single relapse can have devastating consequences. Several immunosuppressive treatments have been shown to be effective in preventing relapse. However, not all patients respond favourably to each treatment, possibly owing to several factors including variability in disease activity and differences in pharmacokinetics and pharmacodynamics of drugs among patients. Thus, identification of predictors of the most suited treatment regimens for individual patients with NMOSD may help guide treatment decisions.